Synthesis of polyvalent inhibitors of controlled molecular weight: structure-activity relationship for inhibitors of anthrax toxin
- PMID: 16827573
- DOI: 10.1021/bm060210p
Synthesis of polyvalent inhibitors of controlled molecular weight: structure-activity relationship for inhibitors of anthrax toxin
Abstract
We describe a novel method to synthesize activated polymers of controlled molecular weight and apply this method to investigate the relationship between the structure and activity of polyvalent inhibitors of anthrax toxin. In particular, we observe an initial sharp increase in potency with increasing ligand density, followed by a plateau where potency is independent of ligand density. Our simple strategy for designing polyvalent inhibitors of controlled molecular weight and ligand density will be broadly applicable for designing inhibitors for a variety of pathogens and toxins, and for elucidating structure-activity relationships in these systems. Our results also demonstrate a role for kinetics in influencing inhibitory potency in polyvalent systems. Finally, our work presents a synthetic route to polyvalent inhibitors that are more structurally defined and effective in vivo. This control over inhibitor composition will be generally useful for the optimization of inhibitor potency and pharmacokinetics, and for the eventual application of these molecules in vivo.
Similar articles
-
Statistical pattern matching facilitates the design of polyvalent inhibitors of anthrax and cholera toxins.Nat Biotechnol. 2006 May;24(5):582-6. doi: 10.1038/nbt1204. Epub 2006 Apr 23. Nat Biotechnol. 2006. PMID: 16633350
-
Functional characterization of peptide-based anthrax toxin inhibitors.Mol Pharm. 2005 Sep-Oct;2(5):367-72. doi: 10.1021/mp050040f. Mol Pharm. 2005. PMID: 16196489
-
Polyvalent inhibitors of anthrax toxin that target host receptors.Proc Natl Acad Sci U S A. 2006 Sep 5;103(36):13509-13. doi: 10.1073/pnas.0509870103. Epub 2006 Aug 28. Proc Natl Acad Sci U S A. 2006. PMID: 16938891 Free PMC article.
-
Polyvalency: a promising strategy for drug design.Biotechnol Bioeng. 2008 Oct 15;101(3):429-34. doi: 10.1002/bit.22056. Biotechnol Bioeng. 2008. PMID: 18727104 Review.
-
Use of phage display and polyvalency to design inhibitors of protein-protein interactions.Methods Mol Biol. 2004;261:213-28. doi: 10.1385/1-59259-762-9:213. Methods Mol Biol. 2004. PMID: 15064461 Review.
Cited by
-
Design of monodisperse and well-defined polypeptide-based polyvalent inhibitors of anthrax toxin.Angew Chem Int Ed Engl. 2014 Jul 28;53(31):8037-40. doi: 10.1002/anie.201400870. Epub 2014 Apr 6. Angew Chem Int Ed Engl. 2014. PMID: 24706570 Free PMC article.
-
Polymer-Based Therapeutics.Macromolecules. 2009 Jan 13;42(1):3-13. doi: 10.1021/ma801782q. Macromolecules. 2009. PMID: 21494423 Free PMC article.
-
Materials science. Polymer therapeutics.Science. 2007 Aug 31;317(5842):1182-3. doi: 10.1126/science.1145951. Science. 2007. PMID: 17761873 Free PMC article. No abstract available.
-
Obstructing toxin pathways by targeted pore blockage.Chem Rev. 2012 Dec 12;112(12):6388-430. doi: 10.1021/cr300141q. Epub 2012 Oct 11. Chem Rev. 2012. PMID: 23057504 Free PMC article. Review. No abstract available.
-
General synthetic route to cell-permeable block copolymers via ROMP.J Am Chem Soc. 2009 Jun 3;131(21):7327-33. doi: 10.1021/ja809284s. J Am Chem Soc. 2009. PMID: 19469577 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources